heard on 27 June and declared inadmissible. Second directions and evidential hearings On 7 July, GOSH applied to the High Court for a further hearing. The formal application asked the court to evaluate the claims made about new evidence and it set out the difficulties that the hospital had experienced with the Declarations made by the judge on 11 April. On Monday 10 July, the case again came before Mr Justice Francis. GOSH disputed claims made by Charlie's parents that there was new evidence; it had been forced to come back to court after lawyers for the parents had threatened judicial review. The parents asked for a further full hearing in two weeks time and they asked the judge to step down on the basis that he had already made up his mind. These applications were both rejected. The judge said he was the best person to evaluate any new evidence; he had heard the case thus far and he promised the parents a fair hearing. He would deal with the case on the basis of evidence not tweets. He expressed an understanding of the parents position "I understand parents will grasp at any possibility of hope." Of the requested two-week delay he said "doctors and nurses were under 'extreme strain' with the case dragging on ... Staff feel it is desperately unfair to Charlie ... week after week knowing that every step they take for Charlie is against his welfare." Directions were given for a further hearing on Thursday 13 July, asking the parents to set out any new evidence they had on the day before. On 13 and 14 July the parents' fresh evidence, set out in a letter sent by the parents' legal team to GOSH a few days after the decision of the European court, was presented to the court. The new evidence was summarised as: the Bambino Gesu Children's Hospital, Rome is willing to accept the transfer of Charlie; Dr. Hirano and the associated medical centre in the USA remain willing to accept the transfer of Charlie; on the basis of new laboratory findings, Dr. Hirano considers: the likelihood of a positive effect and benefits to Charlie of the proposed nucleoside therapy to be markedly improved compared to the views expressed in court; the likelihood that the proposed nucleoside therapy will cross the blood brain barrier to be significantly enhanced. In spite of these assertions,